Covid 19
Última evidencia
Palabras clave:
covid 19, coronavirus, pandemia
Resumen
Ante la gran expectativa mundial por la nueva epidemia de coronavirus, la revista Práctica Familiar Rural pone a disposición ha estudiantes y profesionales de la salud, y de la sociedad en general, una lectura crítica de la evidencia actualizada sobre la nueva epidemia.
Descargas
La descarga de datos todavía no está disponible.
Biografía del autor/a
Diego Herrera, Saludesa
David Gaus, Andean Health and Develoment
Citas
1. Zhu N et al: A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. ePub, 2020
2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses: The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 5:536-44, 2020
3. International Committee on Taxonomy of Viruses: Naming the 2019 Coronavirus. ICTV website. Accessed March 27, 2020. https://talk.ictvonline.org/
4. WHO: Coronavirus Disease 2019 (COVID-19): Situation Report--51. WHO website. Published March 11, 2020. Accessed March 27, 2020. https://www-who-int.proxy.lib.mcw.edu/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf
5. Centre for Evidence-Based Medicine: Global Covid-19 Case Fatality Rates. CEBM website. Updated March 27, 2020. Accessed March 27, 2020. https://www.cebm.net/global-covid-19-case-fatality-rates
6. Luo L, Liu D, Liao X, et al. Modes of contact and risk of transmision in COVID-19 among close contacts.
7. Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. British medical journal. 2020 Abril 2; 369
8. Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. doi:10.1056/NEJMoa2002032
9. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. ePub: 31 March 2020. DOI: http://dx.doi.org/10.15585/mmwr.mm6913e2external icon
10. OMS. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). OMS; 2020.
11. Ortiz-Prado, E.; Simbaña-Rivera, K.; Gomez-Barreno, L.; Rubio-Neira, M.; Guaman, L.P.; Kyriakidis, N.; Muslin, C.; Gomez-Jaramillo, A.M.; Barba, C.; Cevallos, D.; Sanchez-San Miguel, H.; Unigarro, L.; Zalakeviciute, R.; Gadian, N.; López-Cortés, A. Clinical, Molecular and Epidemiological Characterization of the SARS-CoV2 Virus and the Coronavirus Disease 2019 (COVID-19): A Comprehensive Literature Review. PrePrints. 2020 Abril 16; 16.
12. Huang C et al: Clinical features of patients infected with the 2019 novel coronavirus in Wuhan, China. Lancet. ePub, 2020
13. Centre for Evidence-Based Medicine: Global Covid-19 Case Fatality Rates. CEBM website. Updated March 27, 2020. Accessed March 27, 2020. https://www.cebm.net/global-covid-19-case-fatality-rates/
14. Zhao J, Yang Y, Huang H, et al. Relationship between the ABO Blood group and the Covid-19 Susceptibility. medRxiv. doi: https://doi.org/10.1101/2020.03.11.20031096
15. Chen N et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. ePub, 2020
16. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, Zhang J, Zhao C. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. - J. Med. Virol. - April 15, 2020;
17. Chow EJ, Schwartz NG, Tobolowsky FA, et al. Symptom Screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King County, Washington. JAMA. 2020;323(20):2087–2089. doi:10.1001/jama.2020.6637
18. Smyth C. Smell loss has little effect on coronavirus case tallies. The Times. 2020 May
19. Menni C, Sudre CH, Steves CJ, et al. Quantifying additional COVID-19 symptoms will save lives. Lancet. 2020 June 4.
20. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19): China, 2020. China CDC Weekly. 2020; 2(8): p. 113-122.
21. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020.
22. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020:S0140-6736(20)30566-3. Lancet. 2020 March; 395: p. 1054-62.
23. Madjid M, Connolly AT, Nabutovsky Y, Safavi-Naeini P, Razavi M, Miller CC. Effect of high influenza activity on risk of ventricular arrhythmias requiring therapy in patients with implantable cardiac defibrillators and cardiac resynchronization therapy defibrillators. American Journal of Cardiology. 2019; 124(1): p. 44-50.
24. Peretto G., Sala S., Rizzo S. Arrhythmias in myocarditis: state of the art. Heart Rhythm. 2019;16:793–801
25. Cowan LT, Lutsey PL, Pankow JS, Matsushita K, Ishigami J, Lakshminarayan K. Inpatient and outpatient infection as a trigger of cardiovascular disease: the ARIC study. J Am Heart Assoc. 2018;7(22):e009683-e009683. doi:10.1161/JAHA.118.009683
26. Madjid M, Casscells SW. Of birds and men: cardiologists’ role in influenza pandemics. Lancet. 2004;364(9442):1309. doi:10.1016/S0140-6736(04)17176-6
27. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020:S2213-2600(20)30076-X. doi:10.1016/S2213-2600(20)30076-X
28. Stefanini G, Montorfano M, Trabattoni D, et al. ST-Elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation. 2020. doi.org/10.1161/CIRCULATIONAHA.120.047525
29. Madjid M, Casscells SW. Of birds and men: cardiologists’ role in influenza pandemics. Lancet. 2004;364(9442):1309. doi:10.1016/S0140-6736(04)17176-6
30. Stefanini G, Montorfano M, Trabattoni D, et al. ST-Elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation. 2020. doi.org/10.1161/CIRCULATIONAHA.120.047525
31. Mahmud E, Dauerman HL, et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic,CONSENSUS STATEMENT from the Society of cardiovascular angiography and interventions (SCAI), American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). Journal of the American College of Cardiology (2020), doi https://doi.org/10.1016/j.jacc.2020.04.039. PMID:32330544
32. Barnes, G.D., Burnett, A., Allen, A. et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis (2020). https://doi.org/10.1007/s11239-020-02138-z
33. Klok F, Kruipb M, Van der Meerc N, Arbousd M, Gommerse D, Kant K et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. https://doi.org/10.1016/j.thromres.2020.04.013)
34. Bridwel Rachel, Brit Long and Michael Gottlieb, Neurologic complications of COVID-19, American Journal of Emergency Medicine, Volume 38, Issue 7, Pages 1549.e3-1549.e7, 07- 2020
35. Pinzon RT, Wijaya VO, Buana RB, Al Jody A, Nunsio PN. Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:565. Published 2020 May 29. doi:10.3389/fneur.2020.00565
36. Tan, L., Wang, Q., Zhang, D. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Sig Transduct Target Ther 5, 33 (2020). https://doi.org/10.1038/s41392-020-0148-4
37. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.
38. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497.
39. Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020;192:152-160. doi:10.1016/j.thromres.2020.05.039
40. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020.
41. Luo L, Liu D, Liao X, et al. Modes of contact and risk of transmision in COVID-19 among close contacts.
42. Jewett C, Bailey M, Renwick D. Exclusive: Nearly 600 — And Counting — US Health Workers Have Died Of COVID-19: Kaiser Health News; 2020 [9 June 2020]. Available from: https://khn.org/news/exclusive-investigation-nearly-600-and-counting-us-health-workers-have-diedof-covid-19/.
43. Böhmer MM, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. The Lancet Infectious Diseases. 2020 2020/05/15/].
44. Amanat F, Nguyen T, Chromikova V, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv. https://doi.org/10.1101/2020.03.17.20037713.
45. Hoffman, T., Nissen, K., Krambrich, J., Rönnberg, B Dario Akaberi, Mouna Esmaeilzadeh, Erik Salaneck, Johanna Lindahl & Åke Lundkvist (2020) Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2, Infection Ecology & Epidemiology, 10:1, DOI: 10.1080/20008686.2020.1754538
46. Jalaber C, Lapotre T, Morcet-Delattre T, Ribet F, Jouneau S, Lederlin M. Chest CT in COVID-19 pneumonia: A review of current knowledge. Diagn Interv Imaging. 2020;101(7-8):431-437. doi:10.1016/j.diii.2020.06.001
47. Hosseiny M, Kooraki S, Gholamrezanezhad A, et al. Radiology perspective of Coronavirus Disease 2019 (COVID-19): Lessons from severe acute respiratory syndrome and middle east respiratory syndrome. American Journal of Roentgenology: 1-5. 10.2214/AJR.20.22969
48. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020;295(3):715-721. doi:10.1148/radiol.2020200370
49. Ding X, Xu J, Zhou J, Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. Eur J Radiol. 2020;127:109009. doi:10.1016/j.ejrad.2020.109009
50. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr 2020 April 22
51. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395:1607-1608
52. Feldstein L, Rose E, Horwitz S, et al. Multisystem Inflammatory Syndrome in US Children and Adolescentes. NEJM 2020 Julio 23; 383:334-346
53. WHO: Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected: Interim Guidance. WHO website. Updated March 13, 2020. Accessed March 27, 2020. https://www-who-int.proxy.lib.mcw.edu/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
54. United States Centers for Disease Control and Prevention. Discontinuation of In-Home isolation for immunocompromised persons with COVID-19 (Interim Guidance). https://www.cdc.gov/coronavirus/2019-ncov/hcp/ending-isolation.html (Accessed on March 18, 2020).
55. Barnes, G.D., Burnett, A., Allen, A. et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis (2020). https://doi.org/10.1007/s11239-020-02138-z
56. SEHH / SETH. Recomendaciones para el control de anticoagulación en la situación actual de epidemia por coronavirus. 24-Marzo-2020; disponible en: www.seth.org
57. ASH (American Society of Haematology). COVID-19 and Coagulopathy: frequently asked questions; version 1.0; April 1, 2020. Disponible en www.ash.org
58. Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications From Clinical Features to Pathological Findings. Circulation 2020;Apr 16:[Epub ahead of print] https://www.ahajournals. org/doi/10.1161/CIRCULATIONAHA.120.046988.
59. Paul Little Non-steroidal anti-inflammatory drugs and covid-19 m1185 10.1136/ bmj.m1185 http://www.bmj.com/lookup/doi/10.1136/bmj.m1185.
60. Pillinger MH, Capodici C, Rosenthal P, et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. ProcNatl Acad Sci USA 1998;95:14540.
61. Aliae A.R. Mohamed-Husseina, Karim M.E. Alyb, Mohamed-Eltaher, Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy? Hypotheses · June 2020
62. Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective [published online ahead of print, 2020 Jun 27]. Diabetes Metab Syndr. 2020;14(5):971-978. doi:10.1016/j.dsx.2020.06.054
63. Johnson Raymond M, Vinetz Joseph M. Dexamethasone in the management of covid -19 BMJ 2020; 370 :m2648
64. RECOVERY (Randomised Evaluation of COVid-19 therapy. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. [internet] Jun 2020. Disponible en: https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19
65. Van Doremalen N, Lloyd-Smith J, MUnster v, et al. Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. medRxiv preprint. https://doi.org/10.1101/2020.03.09.2003321
66. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) [published online ahead of print, 2020 May 1]. JAMA Cardiol. 2020;e201834. doi:10.1001/jamacardio.2020.1834
67. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State [published online ahead of print, 2020 May 11]. JAMA. 2020;323(24):2493-2502. doi:10.1001/jama.2020.8630
68. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi:10.1016/j.antiviral.2020.104787
69. Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. Am J Trop Med Hyg. 2020;102(6):1156-1157. doi:10.4269/ajtmh.20-0271
70. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID19 comp
71. Jin YH et al: A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 7(1):4, 2020
72. Harrison C: Coronavirus puts drug repurposing on the fast track [news article]. Nat Biotechnol. ePub, 2020
73. Cao B et al: A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. ePub, 2020
74. Agostini ML et al: Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 9(2), 2018
75. Sheahan TP et al: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 11(1):222, 2020
76. FDA: FDA Advises Patients on Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for COVID-19. Updated March 19, 2020. Accessed March 27, 2020. https://www-fda-gov.proxy.lib.mcw.edu/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19
77. Prevention, Diagnosis, and Treatment of VTE in Patients With COVID-19: CHEST Guideline and Expert Panel Report.
78. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Jimenez D, LeGal G, Rali P, Wells P - Chest - June 2, 2020
79. Folegatti P., Ewer K., Parvinder, A., Brian, A., et all, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, Published online July 20, 2020 https://doi.org/10.1016/S0140-6736(20)31604-4
80. Lurie N, Sharfstein JM, Goodman JL. The development of COVID-19 vaccines: safeguards needed. JAMA 2020; published online July 6. https://doi.org.10.1001/jama.2020.12461.
2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses: The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 5:536-44, 2020
3. International Committee on Taxonomy of Viruses: Naming the 2019 Coronavirus. ICTV website. Accessed March 27, 2020. https://talk.ictvonline.org/
4. WHO: Coronavirus Disease 2019 (COVID-19): Situation Report--51. WHO website. Published March 11, 2020. Accessed March 27, 2020. https://www-who-int.proxy.lib.mcw.edu/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf
5. Centre for Evidence-Based Medicine: Global Covid-19 Case Fatality Rates. CEBM website. Updated March 27, 2020. Accessed March 27, 2020. https://www.cebm.net/global-covid-19-case-fatality-rates
6. Luo L, Liu D, Liao X, et al. Modes of contact and risk of transmision in COVID-19 among close contacts.
7. Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. British medical journal. 2020 Abril 2; 369
8. Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. doi:10.1056/NEJMoa2002032
9. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. ePub: 31 March 2020. DOI: http://dx.doi.org/10.15585/mmwr.mm6913e2external icon
10. OMS. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). OMS; 2020.
11. Ortiz-Prado, E.; Simbaña-Rivera, K.; Gomez-Barreno, L.; Rubio-Neira, M.; Guaman, L.P.; Kyriakidis, N.; Muslin, C.; Gomez-Jaramillo, A.M.; Barba, C.; Cevallos, D.; Sanchez-San Miguel, H.; Unigarro, L.; Zalakeviciute, R.; Gadian, N.; López-Cortés, A. Clinical, Molecular and Epidemiological Characterization of the SARS-CoV2 Virus and the Coronavirus Disease 2019 (COVID-19): A Comprehensive Literature Review. PrePrints. 2020 Abril 16; 16.
12. Huang C et al: Clinical features of patients infected with the 2019 novel coronavirus in Wuhan, China. Lancet. ePub, 2020
13. Centre for Evidence-Based Medicine: Global Covid-19 Case Fatality Rates. CEBM website. Updated March 27, 2020. Accessed March 27, 2020. https://www.cebm.net/global-covid-19-case-fatality-rates/
14. Zhao J, Yang Y, Huang H, et al. Relationship between the ABO Blood group and the Covid-19 Susceptibility. medRxiv. doi: https://doi.org/10.1101/2020.03.11.20031096
15. Chen N et al: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. ePub, 2020
16. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, Zhang J, Zhao C. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. - J. Med. Virol. - April 15, 2020;
17. Chow EJ, Schwartz NG, Tobolowsky FA, et al. Symptom Screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King County, Washington. JAMA. 2020;323(20):2087–2089. doi:10.1001/jama.2020.6637
18. Smyth C. Smell loss has little effect on coronavirus case tallies. The Times. 2020 May
19. Menni C, Sudre CH, Steves CJ, et al. Quantifying additional COVID-19 symptoms will save lives. Lancet. 2020 June 4.
20. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19): China, 2020. China CDC Weekly. 2020; 2(8): p. 113-122.
21. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020.
22. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020:S0140-6736(20)30566-3. Lancet. 2020 March; 395: p. 1054-62.
23. Madjid M, Connolly AT, Nabutovsky Y, Safavi-Naeini P, Razavi M, Miller CC. Effect of high influenza activity on risk of ventricular arrhythmias requiring therapy in patients with implantable cardiac defibrillators and cardiac resynchronization therapy defibrillators. American Journal of Cardiology. 2019; 124(1): p. 44-50.
24. Peretto G., Sala S., Rizzo S. Arrhythmias in myocarditis: state of the art. Heart Rhythm. 2019;16:793–801
25. Cowan LT, Lutsey PL, Pankow JS, Matsushita K, Ishigami J, Lakshminarayan K. Inpatient and outpatient infection as a trigger of cardiovascular disease: the ARIC study. J Am Heart Assoc. 2018;7(22):e009683-e009683. doi:10.1161/JAHA.118.009683
26. Madjid M, Casscells SW. Of birds and men: cardiologists’ role in influenza pandemics. Lancet. 2004;364(9442):1309. doi:10.1016/S0140-6736(04)17176-6
27. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020:S2213-2600(20)30076-X. doi:10.1016/S2213-2600(20)30076-X
28. Stefanini G, Montorfano M, Trabattoni D, et al. ST-Elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation. 2020. doi.org/10.1161/CIRCULATIONAHA.120.047525
29. Madjid M, Casscells SW. Of birds and men: cardiologists’ role in influenza pandemics. Lancet. 2004;364(9442):1309. doi:10.1016/S0140-6736(04)17176-6
30. Stefanini G, Montorfano M, Trabattoni D, et al. ST-Elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation. 2020. doi.org/10.1161/CIRCULATIONAHA.120.047525
31. Mahmud E, Dauerman HL, et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic,CONSENSUS STATEMENT from the Society of cardiovascular angiography and interventions (SCAI), American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). Journal of the American College of Cardiology (2020), doi https://doi.org/10.1016/j.jacc.2020.04.039. PMID:32330544
32. Barnes, G.D., Burnett, A., Allen, A. et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis (2020). https://doi.org/10.1007/s11239-020-02138-z
33. Klok F, Kruipb M, Van der Meerc N, Arbousd M, Gommerse D, Kant K et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. https://doi.org/10.1016/j.thromres.2020.04.013)
34. Bridwel Rachel, Brit Long and Michael Gottlieb, Neurologic complications of COVID-19, American Journal of Emergency Medicine, Volume 38, Issue 7, Pages 1549.e3-1549.e7, 07- 2020
35. Pinzon RT, Wijaya VO, Buana RB, Al Jody A, Nunsio PN. Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:565. Published 2020 May 29. doi:10.3389/fneur.2020.00565
36. Tan, L., Wang, Q., Zhang, D. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Sig Transduct Target Ther 5, 33 (2020). https://doi.org/10.1038/s41392-020-0148-4
37. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.
38. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497.
39. Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020;192:152-160. doi:10.1016/j.thromres.2020.05.039
40. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020.
41. Luo L, Liu D, Liao X, et al. Modes of contact and risk of transmision in COVID-19 among close contacts.
42. Jewett C, Bailey M, Renwick D. Exclusive: Nearly 600 — And Counting — US Health Workers Have Died Of COVID-19: Kaiser Health News; 2020 [9 June 2020]. Available from: https://khn.org/news/exclusive-investigation-nearly-600-and-counting-us-health-workers-have-diedof-covid-19/.
43. Böhmer MM, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. The Lancet Infectious Diseases. 2020 2020/05/15/].
44. Amanat F, Nguyen T, Chromikova V, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv. https://doi.org/10.1101/2020.03.17.20037713.
45. Hoffman, T., Nissen, K., Krambrich, J., Rönnberg, B Dario Akaberi, Mouna Esmaeilzadeh, Erik Salaneck, Johanna Lindahl & Åke Lundkvist (2020) Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2, Infection Ecology & Epidemiology, 10:1, DOI: 10.1080/20008686.2020.1754538
46. Jalaber C, Lapotre T, Morcet-Delattre T, Ribet F, Jouneau S, Lederlin M. Chest CT in COVID-19 pneumonia: A review of current knowledge. Diagn Interv Imaging. 2020;101(7-8):431-437. doi:10.1016/j.diii.2020.06.001
47. Hosseiny M, Kooraki S, Gholamrezanezhad A, et al. Radiology perspective of Coronavirus Disease 2019 (COVID-19): Lessons from severe acute respiratory syndrome and middle east respiratory syndrome. American Journal of Roentgenology: 1-5. 10.2214/AJR.20.22969
48. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020;295(3):715-721. doi:10.1148/radiol.2020200370
49. Ding X, Xu J, Zhou J, Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. Eur J Radiol. 2020;127:109009. doi:10.1016/j.ejrad.2020.109009
50. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr 2020 April 22
51. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395:1607-1608
52. Feldstein L, Rose E, Horwitz S, et al. Multisystem Inflammatory Syndrome in US Children and Adolescentes. NEJM 2020 Julio 23; 383:334-346
53. WHO: Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected: Interim Guidance. WHO website. Updated March 13, 2020. Accessed March 27, 2020. https://www-who-int.proxy.lib.mcw.edu/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
54. United States Centers for Disease Control and Prevention. Discontinuation of In-Home isolation for immunocompromised persons with COVID-19 (Interim Guidance). https://www.cdc.gov/coronavirus/2019-ncov/hcp/ending-isolation.html (Accessed on March 18, 2020).
55. Barnes, G.D., Burnett, A., Allen, A. et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis (2020). https://doi.org/10.1007/s11239-020-02138-z
56. SEHH / SETH. Recomendaciones para el control de anticoagulación en la situación actual de epidemia por coronavirus. 24-Marzo-2020; disponible en: www.seth.org
57. ASH (American Society of Haematology). COVID-19 and Coagulopathy: frequently asked questions; version 1.0; April 1, 2020. Disponible en www.ash.org
58. Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications From Clinical Features to Pathological Findings. Circulation 2020;Apr 16:[Epub ahead of print] https://www.ahajournals. org/doi/10.1161/CIRCULATIONAHA.120.046988.
59. Paul Little Non-steroidal anti-inflammatory drugs and covid-19 m1185 10.1136/ bmj.m1185 http://www.bmj.com/lookup/doi/10.1136/bmj.m1185.
60. Pillinger MH, Capodici C, Rosenthal P, et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. ProcNatl Acad Sci USA 1998;95:14540.
61. Aliae A.R. Mohamed-Husseina, Karim M.E. Alyb, Mohamed-Eltaher, Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy? Hypotheses · June 2020
62. Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective [published online ahead of print, 2020 Jun 27]. Diabetes Metab Syndr. 2020;14(5):971-978. doi:10.1016/j.dsx.2020.06.054
63. Johnson Raymond M, Vinetz Joseph M. Dexamethasone in the management of covid -19 BMJ 2020; 370 :m2648
64. RECOVERY (Randomised Evaluation of COVid-19 therapy. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. [internet] Jun 2020. Disponible en: https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19
65. Van Doremalen N, Lloyd-Smith J, MUnster v, et al. Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. medRxiv preprint. https://doi.org/10.1101/2020.03.09.2003321
66. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19) [published online ahead of print, 2020 May 1]. JAMA Cardiol. 2020;e201834. doi:10.1001/jamacardio.2020.1834
67. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State [published online ahead of print, 2020 May 11]. JAMA. 2020;323(24):2493-2502. doi:10.1001/jama.2020.8630
68. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi:10.1016/j.antiviral.2020.104787
69. Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. Am J Trop Med Hyg. 2020;102(6):1156-1157. doi:10.4269/ajtmh.20-0271
70. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID19 comp
71. Jin YH et al: A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 7(1):4, 2020
72. Harrison C: Coronavirus puts drug repurposing on the fast track [news article]. Nat Biotechnol. ePub, 2020
73. Cao B et al: A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. ePub, 2020
74. Agostini ML et al: Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 9(2), 2018
75. Sheahan TP et al: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 11(1):222, 2020
76. FDA: FDA Advises Patients on Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for COVID-19. Updated March 19, 2020. Accessed March 27, 2020. https://www-fda-gov.proxy.lib.mcw.edu/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19
77. Prevention, Diagnosis, and Treatment of VTE in Patients With COVID-19: CHEST Guideline and Expert Panel Report.
78. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Jimenez D, LeGal G, Rali P, Wells P - Chest - June 2, 2020
79. Folegatti P., Ewer K., Parvinder, A., Brian, A., et all, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, Published online July 20, 2020 https://doi.org/10.1016/S0140-6736(20)31604-4
80. Lurie N, Sharfstein JM, Goodman JL. The development of COVID-19 vaccines: safeguards needed. JAMA 2020; published online July 6. https://doi.org.10.1001/jama.2020.12461.
Publicado
2020-07-31
Cómo citar
1.
Herrera D, Gaus D. Covid 19: Última evidencia. PFR [Internet]. 31 de julio de 2020 [citado 11 de mayo de 2024];5(2). Disponible en: https://practicafamiliarrural.org/index.php/pfr/article/view/159
Sección
Artículos de revisión
